A single-arm Phase II study evaluating combination chemotherapy utilizing oral etoposide and irinotecan for platinum-resistant and taxane-pretreated ovarian cancer has started. The aim of this study is to evaluate the efficacy and safety of this regimen as a test arm regimen in a subsequent Phase III trial. Patients with platinum-resistant and taxane-pretreated ovarian cancer are given etoposide at 50 mg/m 2 p.o. from days 1 to 21 and irinotecan 70 mg/m 2 i.v. at days 1 and 15, repeated every 28 days, up to six cycles. A total of 60 patients will be enrolled at 36 institutions. The primary endpoint is response rate. The secondary endpoints include adverse events and progression-free and overall survival.
INTRODUCTION
Ovarian cancer is one of the most lethal gynecologic cancers in Japan. The first-line standard chemotherapy regimen is carboplatin plus paclitaxel (1, 2) . Although first-line chemotherapy is very effective, more than 60% of the patients with an advanced stage will die of recurrent disease. After relapse, the choice of second line chemotherapy depends on 'platinum-free interval (PFI)', which is prognostic and predictive for the effect of repeating platinum agents. Usually, the cut-off point of PFI is regarded as 6 months. Patients recurred within 6 months after first-line chemotherapy are regarded as 'platinum-resistant' and receive second-line chemotherapy with single agent such as pegylated liposomal doxorubicin (3), topotecan (3) and gemcitabine (4) as the standard treatment. Many single cytotoxic agents have shown activity against recurrent ovarian cancer; however, response rates generally have been low, such as 6 -12% (3, 4) , and of short duration because of emerging resistance to the monotherapy regimens. Combination chemotherapy may circumvent this resistance and halt progression of disease, because lower dose of two drugs with different mechanism may reduce the toxicity and enhance the efficacy (5).
Irinotecan, a semi-synthetic derivative of camptothecin, is a prodrug with little inherent topoisomerase inhibitory activity and is converted by carboxylesterases to its more active metabolite, SN-38 (7-ethyl-10-hydroxycamptothecin). In vitro, SN-38 is 250 -1000 times more potent than irinotecan as an inhibitor of topoisomerase. For platinum-resistant patients, irinotecan has shown modest activity (6 -8) as monotherapy in weekly, every 2-week and every 3-week schedules.
Etoposide is a semi-synthetic glycosidic derivative of podophyllotoxin (9) . Intravenous dosing of etoposide has been tested in two Phase II studies and shown relatively low response rates (10,11) (0 and 8.3%). On the contrary, oral etoposide has shown better efficacy, whose response rate was 26.8% for patients with platinum-resistant relapse (12) . Topoisomerase-I treatment induces an increase in the S-phase cell population with an increase in topoisomerase-II mRNA expression. Thus, topoisomerase-I can modulate topoisomerase-II levels to enhance the effect of topoisomerase-II inhibitors (13, 14) .
Eder et al. (15) reported the result of the in vivo study. They showed that a combination of irinotecan and etoposide showed more than an additive effect by both the tumor excision assay and tumor growth delay assay.
A Phase I study of topotecan and oral etoposide revealed severe myelosuppression but promising efficacy for ovarian cancer (16) .
The dose-limiting toxicity of irinotecan is diarrhea, different from that of topotecan (myelosuppression). Then, utilizing etoposide with irinotecan may improve the risk -benefit balance of dual inhibition of topoisomerase. The result of the Phase I study was reported in ASCO 2002 (17) .
The recommended dose for further study was oral etoposide: 50 mg/m 2 /days 1 -21 and intravenous irinotecan: 60 mg/m 2 /days 1 and 15, repeated every 4 weeks. In this Phase I study, four objective responses [two complete responses and two partial responses (PRs)] were achieved among 24 patients, including one PR in clear cell.
Nishio et al. (18) reported the result of feasibility study run by selected hospitals in Tohoku and Kyushu districts in Japan. Response rate, time to progression and overall survival were 44%, 9 months and 17 months, respectively. This very promising result lead us to conduct a nationwide Phase II study run by Japan Clinical Oncology Group (JCOG).
The protocol review committee of the JCOG approved this protocol in January 2009 and the study was initiated in April 2009. This trial was registered at UMIN-CTR as UMIN000001837 (http://www.umin.ac.jp/ctr/index.htm).
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OBJECTIVES
The aim of this study is to evaluate the safety and efficacy of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian, tubal and peritoneal cancer as the test arm regimen in a subsequent Phase III trial. 
ENDPOINTS
The primary endpoint is response rate in all eligible patients. For patients with measurable lesion, response is evaluated according to the RECIST criteria (19) . For patients with nonmeasurable lesion, response is evaluated according to the GCIG CA-125 criteria (20) . The secondary endpoints are progression-free survival, overall survival and adverse events. Overall survival is defined as days from registration to death from any cause, and it is censored at the last followup day when the patient is alive. Progression-free survival is defined as days from registration to disease progression (either of radiological, CA-125, symptomatic) or death from any cause, and it is censored at the latest day when the patient is alive without any evidence of progression.
ELIGIBILITY CRITERIA
INCLUSION CRITERIA
For inclusion in the study, patients are required to fulfill all of the following criteria: (i) cytologically or histologically proven ovarian, tubal or peritoneal cancer (ii) platinum-resistant disease (iii) taxane-pretreated disease (iv) age: 20-75 years old (v) PS (performance status): 0 -2 (vi) one of the followings, or both of them:
(a) patients have measurable lesion (b) patients have assessable lesion with elevated CA-125 (more than 70 U/ml) (vii) no prior treatment with irinotecan, topotecan or etoposide (viii) no prior radiation to abdomen (ix) oral intake without parenteral nutrition (x) both of the followings: (a) no drainage to effusion or ascites within 28 days (b) no effusion or ascites to be drained at registration (xi) both of the followings:
(a) no chemotherapy or surgery within 28 days (b) no hormonal or biologic therapy within 14 days (xii) patients without severe organ dysfunction (xiii) written informed consent
EXCLUSION CRITERIA
Patients are excluded if they meet any of the following criteria:
(i) synchronous or metachronous (within 5 years) malignance other than carcinoma in situ or intramucosal cancer (ii) mental disease or mental symptoms that would affect the participant's decision to participate (iii) pregnant or lactating (iv) continuous systemic steroid 
FOLLOW-UP
Enhanced abdominal computed tomography (CT)/magnetic resonance imaging, chest CT/X-rays and tumor marker (CA-125) are evaluated at least every 8 weeks during the protocol treatment. Adverse events are evaluated at least every 2 weeks during the protocol treatment using CTCAE ver. 3.0.
STUDY DESIGN AND STATISTICAL ANALYSIS
This study is a Phase II trial with two-stage design by Southwest Oncology Group (21) to evaluate this regimen as the test arm for a subsequent Phase III trial.
The sample size was determined as follows by the SWOG design. We assumed that the expected value for the primary endpoint of 35% and the threshold value of 20%. In this situation, the sample size ensuring at least 80% power with one-sided a of 5% is 55. Considering the likelihood of some ineligible patients being enrolled, the total number of patients was set at 60.
INTERIM ANALYSIS AND MONITORING
We plan interim analysis for futility after 30 patients enrolled. In house monitoring will be performed every 6 months by the JCOG Data Center to evaluate the study progress and to improve the study quality.
